ArticleBiology of reproduction2026
Mitochondrial-targeted MitoQ attenuates PFOS-induced vasoconstriction and cAMP suppression in human placental arteries†.
Article in Biology of reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Perfluorooctanesulfonic acid (PFOS), a persistent environmental pollutant, is elevated in the plasma of preeclamptic women and may contribute to gestational hypertension. However, its direct effects on placental vascular function remain unclear. This study investigated PFOS' impact on vascular reactivity in human placental chorionic plate arteries (CPAs) and evaluated the therapeutic potential of the mitochondrial-targeted antioxidant mitoquinone (MitoQ). CPAs from normotensive pregnancies were treated with PFOS (10 μM) or vehicle for 24 h. Wire myography assessed contractile responses to KCl and endothelin-1 (ET-1), as well as cyclic adenosine monophosphate (cAMP)-mediated (isoproterenol, forskolin) and cyclic guanosine monophosphate (cGMP)-mediated (sodium nitroprusside, SNP) vasodilation. Adenosine triphosphate (ATP), cAMP, and cGMP levels were quantified, and MitoQ (100 nM) co-treatment was tested for rescue effects. PFOS-exposed CPAs exhibited enhanced maximal contraction to KCl (9.73 ± 0.96 vs. 5.60 ± 0.41 mN) and ET-1 (9.84 ± 1.05 vs. 5.77 ± 0.49 mN). cAMP-dependent relaxation was impaired (isoproterenol: 31.16 ± 4.55% vs. 65.27 ± 6.08%; forskolin: 65.59 ± 2.72% vs. 87.55 ± 1.89%), while SNP-induced cGMP-mediated relaxation remained unaffected. PFOS reduced ATP by 58% (30.43 ± 2.89 vs. 73.71 ± 9.15 μmol/mg) and cAMP by 57% (46.15 ± 9.54 vs. 109.1 ± 8.88 nmol/mg) but did not affect cGMP levels. MitoQ restored ATP/cAMP levels and normalized vascular function, reversing PFOS-induced hypercontractility and cAMP pathway suppression. These findings demonstrate that PFOS directly impairs placental vascular homeostasis via mitochondrial dysfunction and cAMP signaling disruption, implicating it as a mediator of gestational hypertension. Mitochondrial-targeted interventions like MitoQ may mitigate PFOS-associated vascular dysfunction, highlighting therapeutic avenues for high-exposure pregnancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.